{
    "id": 9158,
    "fullName": "SMO amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "SMO amp indicates an increased number of copies of the SMO gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6608,
        "geneSymbol": "SMO",
        "terms": [
            "SMO",
            "CRJS",
            "FZD11",
            "Gx",
            "SMOH"
        ]
    },
    "variant": "amp",
    "createDate": "07/16/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2657,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Odomzo (sonidegib) and Iressa (gefitinib) decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring an EGFR E746_A750del mutation and SMO amplification in culture and inhibited tumor growth in NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).",
            "molecularProfile": {
                "id": 9076,
                "profileName": "EGFR E746_A750del SMO amp"
            },
            "therapy": {
                "id": 2986,
                "therapyName": "Gefitinib + Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3267,
                    "pubMedId": 26124204,
                    "title": "SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26124204"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2656,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Odomzo (sonidegib) did not decrease viability or migration of non-small cell lung cancer cells harboring EGFR E746_A750del and amplification of SMO in culture (PMID: 26124204).",
            "molecularProfile": {
                "id": 9076,
                "profileName": "EGFR E746_A750del SMO amp"
            },
            "therapy": {
                "id": 1428,
                "therapyName": "Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3267,
                    "pubMedId": 26124204,
                    "title": "SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26124204"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2547,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification of SMO conferred acquired resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 26124204).",
            "molecularProfile": {
                "id": 9076,
                "profileName": "EGFR E746_A750del SMO amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3267,
                    "pubMedId": 26124204,
                    "title": "SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26124204"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2658,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Odomzo (sonidegib) and PHA-665752 decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring EGFR E746_A750del and SMO amplification in culture, and resulted in complete response in 100% (8/8) of NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).",
            "molecularProfile": {
                "id": 9076,
                "profileName": "EGFR E746_A750del SMO amp"
            },
            "therapy": {
                "id": 2987,
                "therapyName": "PHA-665752 + Sonidegib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3267,
                    "pubMedId": 26124204,
                    "title": "SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26124204"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 9074,
            "profileName": "SMO amp",
            "profileTreatmentApproaches": [
                {
                    "id": 6118,
                    "name": "SMO Inhibitor",
                    "profileName": "SMO amp"
                }
            ]
        },
        {
            "id": 9076,
            "profileName": "EGFR E746_A750del SMO amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}